O. Aparicio, J. V. Geisberg, E. Sekinger, A. Yang, Z. Moqtaderi et al., Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo, Curr Protoc Mol Biol, vol.69, 2005.

F. Baenke, B. Chaneton, M. Smith, N. Van-den-broek, K. Hogan et al., Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells, Mol Oncol, vol.10, pp.73-84, 2016.

P. Bai and C. Canto, The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease, Cell Metab, vol.16, pp.290-295, 2012.

P. Balasubramanian, L. J. Zhao, and G. Chinnadurai, Nicotinamide adenine dinucleotide stimulates oligomerization, interaction with adenovirus E1A and an intrinsic dehydrogenase activity of CtBP, FEBS Lett, vol.537, pp.157-160, 2003.

A. R. Baudy, T. Dogan, J. E. Flores-mercado, K. P. Hoeflich, F. Su et al., FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973, EJNMMI Res, vol.2, p.22, 2012.

C. Bertolotto, A. P. Hemesath, T. J. Bille, K. Fisher, D. E. Ortonne et al., Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes, J Cell Biol, vol.142, pp.827-835, 1998.

C. Bertolotto, F. Lesueur, S. Giuliano, T. Strub, M. De-lichy et al., A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma, Nature, vol.480, pp.94-98, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01791271

C. Bonet, S. Giuliano, M. Ohanna, K. Bille, A. M. Lacour et al., Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells, J Biol Chem, vol.287, pp.29887-29898, 2012.

C. Canto, K. J. Menzies, and J. Auwerx, NAD + metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus, Cell Metab, vol.22, pp.31-53, 2015.

J. Caramel, E. Papadogeorgakis, L. Hill, G. J. Browne, G. Richard et al., A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma, Cancer Cell, vol.24, pp.466-480, 2013.

F. Ciccarone, M. Zampieri, and P. Caiafa, PARP1 orchestrates epigenetic events setting up chromatin domains, Semin Cell Dev Biol, vol.63, pp.123-134, 2017.

P. Corazao-rozas, P. Guerreschi, M. Jendoubi, F. Andre, A. Jonneaux et al., Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor, Oncotarget, vol.4, pp.1986-1998, 2013.

T. Delgado-goni, M. F. Miniotis, S. Wantuch, H. G. Parkes, R. Marais et al., The BRAF inhibitor vemurafenib activates mitochondrial metabolism and inhibits hyperpolarized pyruvate-lactate exchange in BRAF-mutant human melanoma cells, Mol Cancer Ther, vol.15, pp.2987-2999, 2016.

A. M. Evans, C. D. Dehaven, T. Barrett, M. Mitchell, and E. Milgram, Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems, Anal Chem, vol.81, pp.6656-6667, 2009.

P. Falletta, L. Sanchez-del-campo, J. Chauhan, M. Effern, A. Kenyon et al., Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma, Genes Dev, vol.31, pp.18-33, 2017.

A. A. Grolla, S. Torretta, I. Gnemmi, A. Amoruso, G. Orsomando et al., Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma, Pigment Cell Melanoma Res, vol.28, pp.718-729, 2015.

R. Haq, J. Shoag, P. Andreu-perez, S. Yokoyama, H. Edelman et al.,

, Oncogenic BRAF regulates oxidative metabolism via PGC1? and MITF, Cancer Cell, vol.23, pp.302-315

J. C. Hassel, D. Winnemoller, M. Schartl, and C. Wellbrock, STAT5 contributes to antiapoptosis in melanoma, Melanoma Res, vol.18, pp.378-385, 2008.

S. Heinz, C. Benner, N. Spann, E. Bertolino, Y. C. Lin et al., Simple combinations of lineage-determining transcription factors prime cisregulatory elements required for macrophage and B cell identities, Mol Cell, vol.38, pp.576-589, 2010.

C. Hilmi, L. Larribere, S. Giuliano, K. Bille, J. P. Ortonne et al., IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X L , and survivin, J Invest Dermatol, vol.128, pp.1499-1505, 2008.

K. S. Hoek, O. M. Eichhoff, N. C. Schlegel, U. Dobbeling, N. Kobert et al., In vivo switching of human melanoma cells between proliferative and invasive states, Cancer Res, vol.68, pp.650-656, 2008.

K. Holen, L. B. Saltz, E. Hollywood, K. Burk, and A. R. Hanauske, The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor, Invest New Drugs, vol.26, pp.45-51, 2008.

R. H. Houtkooper, E. Pirinen, and J. Auwerx, Sirtuins as regulators of metabolism and healthspan, Nat Rev Mol Cell Biol, vol.13, pp.225-238, 2012.

W. Hugo, H. Shi, L. Sun, M. Piva, C. Song et al., Non-genomic and immune evolution of melanoma acquiring MAPKi resistance, Cell, vol.162, pp.1271-1285, 2015.

H. Jing and H. Lin, Sirtuins in epigenetic regulation, Chem Rev, vol.115, pp.2350-2375, 2015.

D. B. Johnson, C. M. Lovly, R. J. Sullivan, R. D. Carvajal, and J. A. Sosman, Melanoma driver mutations and immune therapy, Oncoimmunology, vol.5, p.1051299, 2016.

B. E. Kennedy, T. Sharif, E. Martell, C. Dai, Y. Kim et al., NAD + salvage pathway in cancer metabolism and therapy, Pharmacol Res, vol.114, pp.274-283, 2016.

P. Laurette, T. Strub, D. Koludrovic, C. Keime, L. Gras et al., Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells, Elife, vol.4, p.6857, 2015.

H. Li and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics, vol.25, pp.1754-1760, 2009.

H. Liang, D. M. Fekete, and O. M. Andrisani, CtBP2 downregulation during neural crest specification induces expression of Mitf and REST, resulting in melanocyte differentiation and sympathoadrenal lineage suppression, Mol Cell Biol, vol.31, pp.955-970, 2011.

J. J. Luke, K. T. Flaherty, A. Ribas, and G. V. Long, Targeted agents and immunotherapies: optimizing outcomes in melanoma, Nat Rev Clin Oncol, vol.14, pp.463-482, 2017.

K. Maki and K. Ikuta, MEK1/2 induces STAT5-mediated germline transcription of the TCR? locus in response to IL-7R signaling, J Immunol, vol.181, pp.494-502, 2008.

E. Maldi, C. Travelli, A. Caldarelli, N. Agazzone, S. Cintura et al., Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions, Pigment Cell Melanoma Res, vol.26, pp.144-146, 2013.

M. J. Miller, A. D. Kennedy, A. D. Eckhart, L. C. Burrage, J. E. Wulff et al., Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism, J Inherit Metab Dis, vol.38, pp.1029-1039, 2015.

A. Mirmohammadsadegh, M. Hassan, W. Bardenheuer, A. Marini, A. Gustrau et al., STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases, J Invest Dermatol, vol.126, pp.2272-2280, 2006.

J. Muller, O. Krijgsman, J. Tsoi, L. Robert, W. Hugo et al., Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma, Nat Commun, vol.5, p.5712, 2014.

M. Ohanna, S. Giuliano, C. Bonet, V. Imbert, V. Hofman et al., Senescent cells develop a PARP-1 and nuclear factor-?B-associated secretome (PNAS), Genes Dev, vol.25, pp.1245-1261, 2011.

M. Ohanna, C. Bonet, K. Bille, A. M. Davidson, I. Bahadoran et al., SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells, Oncotarget, vol.5, pp.2085-2095, 2014.

M. Onishi, T. Nosaka, K. Misawa, A. L. Mui, D. Gorman et al., Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation, Mol Cell Biol, vol.18, pp.3871-3879, 1998.

T. J. Parmenter, M. Kleinschmidt, K. M. Kinross, S. T. Bond, J. Li et al., Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis, Cancer Discov, vol.4, pp.423-433, 2014.

A. Ravaud, T. Cerny, C. Terret, J. Wanders, B. N. Bui et al., Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study, Eur J Cancer, vol.41, pp.702-707, 2005.

S. K. Ray, H. J. Li, E. Metzger, R. Schule, and A. B. Leiter, CtBP and associated LSD1 are required for transcriptional activation by NeuroD1 in gastrointestinal endocrine cells, Mol Cell Biol, vol.34, pp.2308-2317, 2014.

S. Riesenberg, A. Groetchen, R. Siddaway, T. Bald, J. Reinhardt et al., MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment, Nat Commun, vol.6, p.8755, 2015.

M. I. Rodriguez, A. Peralta-leal, O. Valle, F. Rodriguez-vargas, J. M. Gonzalez-flores et al., PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation, PLoS Genet, vol.9, p.1003531, 2013.

X. Sun, V. R. Elangovan, B. Mapes, S. M. Camp, S. Sammani et al., The NAMPT promoter is regulated by mechanical stress, signal transducer and activator of transcription 5, and acute respiratory distress syndrome-associated genetic variants, Am J Respir Cell Mol Biol, vol.51, pp.660-667, 2014.

K. Tateishi, H. Wakimoto, A. J. Iafrate, S. Tanaka, F. Loebel et al., Extreme vulnerability of IDH1 mutant cancers to NAD + depletion, Cancer Cell, vol.28, pp.773-784, 2015.

P. Tripathi, S. Kurtulus, S. Wojciechowski, A. Sholl, K. Hoebe et al., STAT5 is critical to maintain effector CD8 + T cell responses, J Immunol, vol.185, pp.2116-2124, 2010.

A. Verfaillie, H. Imrichova, Z. K. Atak, M. Dewaele, F. Rambow et al., Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state, Nat Commun, vol.6, p.6683, 2015.

A. Von-heideman, A. Berglund, R. Larsson, and P. Nygren, Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data, Cancer Chemother Pharmacol, vol.65, pp.1165-1172, 2010.

W. Wachsman, V. Morhenn, T. Palmer, L. Walls, T. Hata et al., Noninvasive genomic detection of melanoma, Br J Dermatol, vol.164, pp.797-806, 2011.

O. Warburg, On the origin of cancer cells, Science, vol.123, pp.309-314, 1956.

P. S. Ward and C. B. Thompson, Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate, Cancer Cell, vol.21, pp.297-308, 2012.

T. Ye, A. R. Krebs, M. A. Choukrallah, C. Keime, F. Plewniak et al., seqMINER: an integrated ChIP-seq data interpretation platform, Nucleic Acids Res, vol.39, p.35, 2011.

Y. Zhang, T. Liu, C. A. Meyer, J. Eeckhoute, D. S. Johnson et al., Model-based analysis of ChIP-seq (MACS), Genome Biol, vol.9, 2008.

, six months after the full-issue publication date, Creative Commons License (Attribution-NonCommercial 4.0 International), as described )